

Sheldon Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4994228/publications.pdf>

Version: 2024-02-01

64
papers

12,557
citations

126858

33
h-index

175177

52
g-index

65
all docs

65
docs citations

65
times ranked

11995
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptin and renal disease. American Journal of Kidney Diseases, 2002, 39, 1-11.	2.1	6,157
2	Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8015-8020.	3.3	859
3	A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 395-423.	9.6	575
4	From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease: Podocyte Injury Comes of Age in Diabetic Nephropathy. Diabetes, 2005, 54, 1626-1634.	0.3	521
5	Diabetic Nephropathy: Mechanisms of Renal Disease Progression. Experimental Biology and Medicine, 2008, 233, 4-11.	1.1	502
6	ACE and ACE2 Activity in Diabetic Mice. Diabetes, 2006, 55, 2132-2139.	0.3	270
7	Diabetic nephropathy and transforming growth factor- β 2: transforming our view of glomerulosclerosis and fibrosis build-up. Seminars in Nephrology, 2003, 23, 532-543.	0.6	233
8	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. , 2019, 7, 2.		213
9	Hydrogen peroxide increases extracellular matrix mRNA through TGF- β 2 in human mesangial cells. Kidney International, 2001, 59, 87-95.	2.6	196
10	Increased Glomerular and Tubular Expression of Transforming Growth Factor- β 21, Its Type II Receptor, and Activation of the Smad Signaling Pathway in the db/db Mouse. American Journal of Pathology, 2001, 158, 1653-1663.	1.9	187
11	Effects of high glucose and TGF- β 21 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney International, 2002, 62, 901-913.	2.6	182
12	Blockade of Vascular Endothelial Growth Factor Signaling Ameliorates Diabetic Albuminuria in Mice. Journal of the American Society of Nephrology: JASN, 2006, 17, 3093-3104.	3.0	179
13	Retooling the Creatinine Clearance Equation to Estimate Kinetic GFR when the Plasma Creatinine Is Changing Acutely. Journal of the American Society of Nephrology: JASN, 2013, 24, 877-888.	3.0	169
14	Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF- β 2-induced fibronectin in mesangial cells. Biochemical and Biophysical Research Communications, 2002, 296, 1356-1365.	1.0	161
15	Leptin stimulates type I collagen production in db/db mesangial cells: Glucose uptake and TGF- β 2 type II receptor expression. Kidney International, 2001, 59, 1315-1323.	2.6	126
16	The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF- β 2, increases podocyte motility and albumin permeability. American Journal of Physiology - Renal Physiology, 2009, 297, F85-F94.	1.3	121
17	Reversibility of established diabetic glomerulopathy by anti-TGF- β 2 antibodies in db/db mice. Biochemical and Biophysical Research Communications, 2003, 300, 16-22.	1.0	120
18	The Urine/Plasma Electrolyte Ratio: A Predictive Guide to Water Restriction. American Journal of the Medical Sciences, 2000, 319, 240-244.	0.4	120

#	ARTICLE	IF	CITATIONS
19	Extracellular Signal-Regulated Kinase Mediates Stimulation of TGF- β 1 and Matrix by High Glucose in Mesangial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 2222-2230.	3.0	115
20	Interference with TGF- β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1657-F1665.	1.3	110
21	Podocyte-Derived Vascular Endothelial Growth Factor Mediates the Stimulation of α 3(IV) Collagen Production by Transforming Growth Factor- β 1 in Mouse Podocytes. <i>Diabetes</i> , 2004, 53, 2939-2949.	0.3	101
22	Glycated albumin stimulates TGF- β 1 production and protein kinase C activity in glomerular endothelial cells. <i>Kidney International</i> , 2001, 59, 673-681.	2.6	99
23	Glycated albumin increases oxidative stress, activates NF- κ B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor- β 1 production in macrophage RAW cells. <i>Translational Research</i> , 2003, 141, 242-249.	2.4	99
24	Angiotensin II stimulates α 3(IV) collagen production in mouse podocytes via TGF- β and VEGF signalling: implications for diabetic glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1320-1328.	0.4	98
25	The Urine/Plasma Electrolyte Ratio: A Predictive Guide to Water Restriction. <i>American Journal of the Medical Sciences</i> , 2000, 319, 240-244.	0.4	95
26	Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1700-1710.	0.4	90
27	THE KEY ROLE OF THE TRANSFORMING GROWTH FACTOR- β SYSTEM IN THE PATHOGENESIS OF DIABETIC NEPHROPATHY. <i>Renal Failure</i> , 2001, 23, 471-481.	0.8	88
28	Abnormalities in signaling pathways in diabetic nephropathy. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 51-64.	1.2	88
29	Amadori-glycated albumin in diabetic nephropathy: Pathophysiologic connections. <i>Kidney International</i> , 2000, 58, S40-S44.	2.6	72
30	Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: Pathogenic and therapeutic implications. <i>Translational Research</i> , 2006, 147, 211-219.	2.4	68
31	Renal Lipotoxicity-Associated Inflammation and Insulin Resistance Affects Actin Cytoskeleton Organization in Podocytes. <i>PLoS ONE</i> , 2015, 10, e0142291.	1.1	65
32	Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. <i>Kidney International</i> , 2005, 68, 1554-1561.	2.6	56
33	Retinoids as a potential treatment for experimental puromycin-induced nephrosis. <i>British Journal of Pharmacology</i> , 2003, 139, 823-831.	2.7	54
34	Vascular endothelial growth factor and diabetic nephropathy. <i>Current Diabetes Reports</i> , 2008, 8, 470-476.	1.7	52
35	Effects of Tumor Necrosis Factor- α on Podocyte Expression of Monocyte Chemoattractant Protein-1 and in Diabetic Nephropathy. <i>Nephron Extra</i> , 2015, 5, 1-18.	1.1	36
36	HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, F995-F1004.	1.3	32

#	ARTICLE	IF	CITATIONS
37	Cultured tubule cells from TGF- β 1 null mice exhibit impaired hypertrophy and fibronectin expression in high glucose. <i>Kidney International</i> , 2004, 65, 1191-1204.	2.6	29
38	Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 82-95.	2.0	29
39	Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF- β 1. <i>Kidney International</i> , 2002, 61, 2025-2032.	2.6	26
40	Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F789-F795.	1.3	25
41	Kinetic Glomerular Filtration Rate in Routine Clinical Practice—Applications and Possibilities. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 105-114.	0.6	20
42	The value of kinetic glomerular filtration rate estimation on medication dosing in acute kidney injury. <i>PLoS ONE</i> , 2019, 14, e0225601.	1.1	18
43	Visualizing the mouse podocyte with multiphoton microscopy. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 525-530.	1.0	15
44	Kinetic glomerular filtration rate equation can accommodate a changing body volume: Derivation and usage of the formula. <i>Mathematical Biosciences</i> , 2018, 306, 97-106.	0.9	13
45	The Renin-Angiotensin System in Diabetic Nephropathy. , 2001, 135, 212-221.		11
46	Kinetic Sodium Equation with Built-In Rate of Correction: Aid to Prescribing Therapy for Hyponatremia or Hypernatremia. <i>Journal of Onco-Nephrology</i> , 2017, 1, 204-212.	0.3	10
47	Estimating Creatinine Clearance in the Nonsteady State: The Determination and Role of the True Average Creatinine Concentration. <i>Kidney Medicine</i> , 2019, 1, 207-216.	1.0	7
48	Pathophysiology of Diabetic Nephropathy. , 2020, , 279-296.		7
49	Improving on the Adrogue-Madias Formula. <i>Kidney360</i> , 2021, 2, 365-370.	0.9	7
50	In creatinine kinetics, the glomerular filtration rate always moves the serum creatinine in the opposite direction. <i>Physiological Reports</i> , 2021, 9, e14957.	0.7	5
51	Pathophysiology and Pathogenesis of Diabetic Nephropathy. , 2013, , 2605-2632.		4
52	Response to “Kinetic sodium equation”. <i>Journal of Onco-Nephrology</i> , 2018, 2, 33-34.	0.3	4
53	Hyponatremia in cancer patients: Strategy for safe correction in the hospital. <i>Journal of Onco-Nephrology</i> , 2019, 3, 144-150.	0.3	3
54	Transforming Growth Factor- β 2 and other Cytokines in Experimental and Human Nephropathy. , 2000, , 313-338.		3

#	ARTICLE	IF	CITATIONS
55	Hemoconcentration of Creatinine Minimally Contributes to Changes in Creatinine during the Treatment of Decompensated Heart Failure. <i>Kidney</i> 360, 2022, 3, 1003-1010.	0.9	3
56	Involvement of the transforming growth factor- β system in the pathogenesis of diabetic nephropathy. <i>Clinical and Experimental Nephrology</i> , 2002, 6, 125-129.	0.7	2
57	Transforming Growth Factor- β Signal Transduction in the Pathogenesis of Diabetic Nephropathy. , 2006, , 201-221.		1
58	Physiologic Principles in the Clinical Evaluation of Electrolyte, Water, and Acid-Base Disorders. , 2013, , 2477-2511.		1
59	Pathophysiology of Diabetic Nephropathy. , 2015, , 151-162.		1
60	Perspectives From an Onconephrology Interest Group: Conference Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096258.	0.6	1
61	TRANSFORMING GROWTH FACTOR- β AND OTHER CYTOKINES IN EXPERIMENTAL AND HUMAN DIABETIC NEPHROPATHY. , 0, , 397-432.		1
62	Evolution of the kidney-cancer connection. <i>Journal of Onco-Nephrology</i> , 2019, 3, 88-91.	0.3	0
63	Acute kidney injury incidence, pathogenesis, and outcomes. , 2020, , 269-274.e3.		0
64	[Creatinine] can change in an unexpected direction due to the volume change rate that interacts with kinetic GFR: Potentially positive paradox. <i>Physiological Reports</i> , 2022, 10, e15172.	0.7	0